Charlottesville, VA-Use of molecular analysis for the uroplakin II (UPII) gene may potentially be a more sensitive method than conventional histopathology for identifying lymph node metastasis in patients with urothelial bladder cancer, according to a joint University of Virginia/University of Western Ontario study appearing in Clinical Cancer Research (2001; 7:1516-22).
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.